Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Cash (2016 - 2025)

Vanda Pharmaceuticals' Change in Cash history spans 16 years, with the latest figure at $14.8 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 715.23% year-over-year to $14.8 million; the TTM value through Dec 2025 reached -$17.5 million, up 47.87%, while the annual FY2025 figure was -$17.5 million, 47.87% up from the prior year.
  • Change in Cash for Q4 2025 was $14.8 million at Vanda Pharmaceuticals, up from -$11.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $219.1 million in Q1 2023 and bottomed at -$204.1 million in Q2 2023.
  • The 5-year median for Change in Cash is -$4.6 million (2021), against an average of $1.2 million.
  • The largest annual shift saw Change in Cash soared 5428.21% in 2022 before it crashed 2245.63% in 2023.
  • A 5-year view of Change in Cash shows it stood at $1.5 million in 2021, then skyrocketed by 5428.21% to $85.6 million in 2022, then tumbled by 155.31% to -$47.4 million in 2023, then surged by 103.84% to $1.8 million in 2024, then surged by 715.23% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Change in Cash are $14.8 million (Q4 2025), -$11.0 million (Q3 2025), and -$30.8 million (Q2 2025).